Technomark Life Sciences

Established in 1987 in London for strategic planning to large pharma, today Technomark is an international life science investment group who has successfully merged its product development and venture capital backgrounds, through proactive management. Our investment track record started in with our first (and only) venture capital fund in which we invested in 8 life science companies (4 drug delivery/med-tech; 4 therapeutic), of which we successfully exited 7 of the companies with a very healthy ROI. Since 2009 under our co-funding business model, we share the risk and the cost of clinical studies (30-60%) in exchange for some downstream remuneration. Through our small and hand-selected network of boutique clinical CROs around the world, we invest by co-funding clinical trials, which allows us to be more involved as investors, strategists, and partners, or just first-hand observers. As long-term investors we invest and co-fund the clinical development of our portfolio companies in a hands-on manner. We are small, boutique investor group specializing in clinical development, and as such we try not have many active portfolio companies, because we feel that it takes away from our personal approach. Technomark’s traditions are not rooted in complex derivatives, conflicted transactions, and ethical quandaries. Our basic mandate is to connect innovation and minimal capital, with our tremendous global development knowledge and our significant co-funding contribution. We are a creative company that uses our outside-the-box thinking, combined with our internal resources in product development around the world to add value. We believe that the actual funding is only one component of the many variables required for a successful development program. At the end of the day, the success of our portfolio companies means our success, and we take pride not only in our track record, but more importantly the praise we receive for our integrity, honesty, and camaraderie.